We will have limited operations from 15:00 Wednesday 24 December 2025 (AEDT) until Friday 2 January 2026. Find out how to contact us during the holiday period.
Sponsor content
46 result(s) found, displaying 11 to 20
-
Prescription medicine registrationActive ingredients: fezolinetant.
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for PADCEV enfortumab vedotin 30 mg powder for injection vial.
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for PADCEV enfortumab vedotin 20 mg powder for injection vial.
-
Designation or determinationOrphan Drug
-
Australian public assessment report (AusPar)AusPAR for Padcev (Enfortumab vedotin) for the treatment of adult patients with locally advanced or metastatic urothelial cancer who have previously received a platinum-containing chemotherapy and a programmed receptor-1 or programmed death-ligand-1 inhibitor.
-
Prescription medicine decision summaryPadcev (enfortumab vedotin) is approved to treat adult patients with locally advanced or metastatic urothelial cancer.
-
Prescription medicine registrationActive ingredients: enfortumab vedotin.
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for XOSPATA gilteritinib (as fumarate) 40 mg film-coated tablet blister pack.
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for ADVAGRAF XL tacrolimus 3 mg prolonged-release capsules blister pack.
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for PROGRAF XL tacrolimus 3 mg prolonged-release capsules blister pack.